The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
GCLLSG 2016 | How to explain the ‘watch-and-wait’ period to a CLL patient?
Petra Langerbeins, MD of University of Cologne, Cologne, Germany talks about how to explain the ‘watch-and-wait’ period to chronic lymphocytic leukemia (CLL) patients. Dr Langerbeins states that she explains to patients in this situation, that ‘watch-and-wait’ is the standard of care and acknowledges that some patients worry. In the CLL12 trial (NCT02863718), patients can start early treatment intervention if they are randomized to the ibrutinib arm. The aim is to delay time to first chemoimmunotherapy but also to improve survival.
Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
